Trial
NCT01818479
Phase I/II Study of Treg/Tcon Addback to Partially Matched Related Donor Stem Cells With Myeloablative Conditioning and Post-transplant Cyclophosphamide for High Risk Hematologic Malignancies
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Utah
Collaborators
—
Condition
High Risk Hematologic Malignancies
Intervention
stem cell transplant
Why stopped
Trial discontinued prior to starting Phase II portion due to low accrual.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-08-11